Individual differences in neural sensitization and the role of context in illness from low-level environmental chemical exposures

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 2, 1997, Pages 457-466

  Bell, Iris R ^a,b,d   Schwartz, Gary E ^a,b   Baldwin, Carol M ^b,c   Hardin, Elizabeth E ^a   Klimas, Nancy G ^e,f   Kline, John P ^b   Patarca, Roberto ^e   Song, Zhi Ying ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adaptation; Conditioning; Dopamine; Environmental chemicals; Kindling; Limbic; Multiple chemical sensitivity; Sensitization; Tolerance

Indexed keywords

DOPAMINE; ENVIRONMENTAL CHEMICAL;

ADAPTATION; BEHAVIOR; COMPLEX PARTIAL SEIZURE; CONDITIONING; CONFERENCE PAPER; ENDOCRINE FUNCTION; ENVIRONMENTAL EXPOSURE; HABITUATION; HUMAN; IMMUNOLOGY; KINDLING; LEARNING; LIMBIC SYSTEM; MEMORY; MULTIPLE CHEMICAL SENSITIVITY; NEUROCHEMISTRY; PERCEPTION; PRIORITY JOURNAL; SENSITIZATION; SYMPTOM;

EID: 0031009270     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s2457     Document Type: Conference Paper

References (109)

1. Bell IR, Miller CS, Schwartz GE. An olfactory-limbic model of multiple chemical sensitivity syndrome: possible relationships to kindling and affective spectrum disorders. Biol Psychiatry 32:218-242 (1992).
2. Bell IR, Bootzin RR, Davis T, Hau V, Ritenbaugh C, Johnson KA, Schwartz GE. Time-dependent sensitization of plasma beta-endorphin in community elderly with self-reported environmental chemical odor intolerance. Biol Psychiatry 40:134-143 (1996).
3. Bell IR, Peterson JM, Schwartz GE. Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. J Clin Psychiatry 56:151-160 (1995).
4. Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 50:119-129 (1995).
5. Miller CS. Chemical sensitivity: history and phenomenology. Toxicol Ind Health 10:253-276 (1994).
6. Simon GE, Katon WJ, Sparks PJ. Allergic to life: psychological factors in environmental illness. Am J Psychiatry 147:901-906 (1990).
7. Simon GE, Daniell W, Stockbridge H, Claypoole K, Rosenstock L. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study. Ann Int Med 19:97-103 (1993).
8. Black DW, Rathe A, Goldstein RB. Environmental illness. A controlled study of 26 subjects with "20th century disease." JAMA 264:3166-3170 (1990).
9. Fiedler N, Kipen H, DeLuca J, Kelly-McNeil K, Natelson B. Neuropsychology and psychology of MCS. Toxicol Ind Health 10:545-554 (1994).
10. Ashford NA, Miller CS. Chemical Exposures. Low Levels and High Stakes. New York:Van Nostrand-Reinhold, 1991.
11. Cullen MR. The worker with multiple chemical sensitivities: an overview. Occup Med: State of the Art Reviews 2:655-662 (1987).
12. Fiedler N, Kipen HM, DeLuca J, Kelly-McNeil K, Natelson B. A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosom Med 58:38-49 (1996).
13. Ziem G. Multiple chemical sensitivity: treatment and followup with avoidance and control of chemical exposures. Toxicol Ind Health 8:73-86 (1992).
14. Doty RL, Deems DA, Frye RE, Pelberg R, Shapiro A. Olfactory sensitivity, nasal resistance, and autonomic function in patients with multiple chemical sensitivities. Arch Otolaryngol Head Neck Surg 114:1422-1427 (1988).
15. Bell IR, Markley EJ, King DS, Asher S, Marby D, Kayne H, Greenwald M, Ogar DA, Margen S. Polysymptomatic syndromes and autonomic reactivity to nonfood stressors in individuals with self-reported adverse food reactions. J Am Coll Nutrition 12:227-238 (1993).
16. Randolph TG. Specific adaptation. Ann Allergy 40:333-345 (1978).
17. Meggs WJ. Neurogenic inflammation and sensitivity to environmental chemicals. Environ Health Perspect 101:234-238 (1993).
18. Meggs WJ. Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. Environ Health Perspect 103:54-56 (1995).
19. Ross GH. History and clinical presentation of the chemically sensitive patient. Toxicol Ind Health 8:21-28 (1992).
20. Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Internal Med 154: 2049-2053 (1994).
21. Bell IR, Schwartz GE, Amend D, Peterson JM, Stini WA. Sensitization to early life stress and response to chemical odors in older adults. Biol Psychiatry 35:857-863 (1994).
22. Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health 51:275-282 (1996).
23. Ryan CM, Morrow LA, Hodgson M. Cacosmia and neurobehavioral dysfunction associated with occupational exposure to mixtures of organic solvents. Am J Psychiatry 145:1442-1445 (1988).
24. Morrow LA, Ryan CM, Hodgson MJ, Robin N. Alterations in cognitive and psychological functioning after organic solvent exposure. J Occup Med 32:444-450 (1990).
25. Bell IR, Schwartz GE, Peterson JM, Amend D. Self-reported illness from chemical odors in young adults without clinical syndromes or occupational exposures. Arch Environ Health 48:6-13 (1993).
26. Bell IR, Schwartz GE, Peterson JM, Amend D. Symptom and personality profiles of young adults from a college student population with self-reported illness from foods and chemicals. J Am Coll Nutrition 12:693-702 (1993).
27. Bell IR, Schwartz GE, Peterson JM, Amend D, Stini WA. Possible time-dependent sensitization to xenobiotics: self-reported illness from chemical odors, foods, and opiate drugs in an older adult population. Arch Environ Health 48:315-327 (1993).
28. Bell IR. Neuropsychiatric aspects of sensitivity to low level chemicals: a neural sensitization model. Toxicol Ind Health 10:277-312 (1994).
29. Doty RL, ed. Handbook of Olfaction and Gustation. New York:Marcel Dekker, 1995.
30. Stevens DA, O'Connell RJ. Enhanced sensitivity to androstenone following regular exposure to pemenone. Chemical Senses 20:413-419 (1995).
31. Shipley MT. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium. Brain Res Bull 15:129-142 (1985).
32. Ghantous H, Dencker L, Gabrielsson J, Damelsson BRG, Bergman K. Accumulation and turnover of metabolites of toluene and xylene in nasal mucosa and olfactory bulb in the mouse. Pharmacol Toxicol 66:87-92 (1990).
33. Joy RM. Mode of action of lindane, dieldrin, and related insecticides in the central nervous system. Neurobehav Toxicol Teratol 4:813-823 (1982).
34. Kay LM. Support for the kindling hypothesis in multiple chemical sensitivity syndrome (MCSS) induction. Soc Neuroscience 22:1825 (1996).
35. Stewart J, Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4:289-312 (1993).
36. Gilbert ME, Mack CM. The NMDA blocker, MK-801, suppresses long-term potentiation, kindling, and kindling-induced potentiation of the perforant path in the unanesthetized rat. Brain Res 519:89-96 (1990).
37. Stewart J, Druhan JP. Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. Psychopharmacology 110:125-132 (1993).
38. Karler R, Finnegan KT, Calder LD. Blockade of behavioral sensitization to cocaine and amphetamine by inhibitors of protein synthesis. Brain Res 603:19-24 (1993).
39. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15:353-375 (1992).
40. Mesulam MM. Principles of Behavioral Neurology. Philadelphia:FA Davis, 1985.
41. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 52:259-285 (1993).
42. Rossi J. Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Toxicol 111:87-100 (1996).
43. Adamec RE. Does kindling model anything clinically relevant? Biol Psychiatry 27:249-279 (1990).
44. Gilbert, ME. Repeated exposure to lindane leads to behavioral sensitization and facilitates electrical kindling. Neurotoxicol Teratatol 17:131-141 (1995).
45. Gilbert ME. A characterization of chemical kindling with the pesticide endosulfan. Neurotoxicol Teratol 14:151-158 (1992).
46. Gilbert ME. Neurotoxicants and limbic kindling. In: The Vulnerable Brain and Environmental Risks. Vol 1: Malnutrition and Hazard Assessment (Isaacson RL, Jensen KF, eds). New York:Plenum Press, 1992;173-193.
47. Herzog AG, Seibel MM, Schomer D, Vaitukaitis J, Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 34:1389-1393 (1984).
48. Bell IR, Hardin EE, Baldwin CM, Schwartz GE. Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities. Environ Res 70:84-97 (1995).
49. Bell IR, Baldwin CM, Russek LG, Schwartz GE, Hardin EE. Unpublished data.
50. Bell IR, Bootzin RR, Schwartz GE, Szarek MJ, DiCenso DR, Baldwin CM. Unpublished data.
51. Teicher MH, Glod CA, Surey J, Swett C. Early childhood abuse and limbic system ratings in adult psychiatric outpatients. J Neuropsychiatry Clin Neurosci 5:301-306 (1993).
52. Weilberg JB, Schacter S, Worth J, Pollack MH, Sachs GS, Ives JR, Schomer DL. EEG abnormalities in patients with atypical panic attacks. J Clin Psychiatry 56:358-362 (1995).
53. Locatelli M, Bellodi L, Perna G, Scarone S. EEG power modifications in panic disorder during a temporolimbic activation task: relationships with temporal lobe clinical symptomatology. J Neuropsychiatry Clin Neurosci 5:409-414 (1993).
54. Sorg BA, Hooks MS, Kalivas PW. Neuroanatomy and neurochemical mechanisms of time-dependent sensitization. Toxicol Ind Health 19:369-386 (1994).
55. Alesdatter JE, Kalivas PW. Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J Pharmacol Exp Ther 267:486-495 (1993).
56. Antelman SM. Time-dependent sensitization as the corner-stone for a new approach to pharmacotherapy: drugs as foreign/stressful stimuli. Drug Devel Res 14:1-30 (1988).
57. Antelman SM. Time-dependent sensitization in animals: a possible model of multiple chemical sensitivity in humans. Toxicol Ind Health 10:335-342 (1994).
58. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity. Brain Res Rev 16:223-244 (1991).
59. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4:315-334 (1993).
60. Cunningham ST, Kelley AE. Hyperactivity and sensitization to psychostimulants following cholera toxin infusion into the nucleus accumbens. J Neuroscience 13:2342-2350 (1993).
61. Antelman SM, Caggiula AR, Kocan D, Knopf S, Meyer D, Edwards DJ, Barry H. One experience with "lower" or "higher" intensity stressors respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability. Brain Res 566:276-283 (1991).
62. vonEuler G, Ogren S, Eneroth P, Fuxe K, Gustafsson J. Persistent effects of 80 ppm toluene on dopamine-regulated locomotor activity and prolactin secretion in the male rat. Neurotoxicology 15:621-624 (1994).
63. Sorg BA, Willis JR, Nowatka TC, Ulibarri C, See RE, Westberg HH. A proposed animal neurosensitization model for multiple chemical sensitivity in studies with formalin. Toxicology 111:135-145 (1996).
64. Antelman SM, Caggiula AR, Kiss S, Edwards DJ, Kocan D, Stiller R. Neurochemical and physiological effects of cocaine oscillate with sequential drug treatment: possibly a major factor in drug variability. Neuropsychopharmacology 12:297-306 (1995).
65. Weiss SRB, Post RM, Costello M, Nutt DJ, Tandeciarz S. Carbamazepine retards the development of cocaine-kindled seizures but not sensitization to cocaine-induced hyperactivity. Neuropsychopharmacology 3:273-281 (1990).
66. Eikelboom R, Stewart J. Conditioning of drug-induced physiological responses. Psychol Rev 89:507-528 (1982).
67. Badiani A, Browman KE, Robinson TE. Influence of novel versus home environments on sensitization to the psychomotor stimulant effects of cocaine and amphetamine. Brain Res 674:291-298 (1995).
68. Newlin DB, Thomson JB. Chronic tolerance and sensitization to alcohol in sons of alcoholics. Alc Clin Exp Res 15:399-405 (1991).
69. Stewart J, Vezina P. Extinction procedures abolish conditioned stimulus control but spare sensitized responding to amphetamine. Behav Pharmacol 2:65-71 (1991).
70. Post RM, Weiss SRB, Pert A. The role of context and conditioning in behavioral sensitization to cocaine. Psychopharm Bull 23:425-429 (1987).
71. Jodogne C, Marinelli M, LeMoal M, Piazza PV. Animals predisposed to develop amphetamine self-administration show higher susceptibility to develop contextual conditioning of both amphetamine-induced hyperlocomotion and sensitization. Brain Res 657:236-244 (1994).
72. Antelman SM, Eichler AJ, Black CA, Kocan D. Interchangeability of stress and amphetamine in sensitization. Science 207:329-331 (1980).
73. Kalivas PW, Richardson-Carlson R, van Orden G. Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biol Psychiatry 21:939-950 (1986).
74. Deroche V, Piazza PV, Casolini P, LeMoal M, Simon H. Sensitization to the psychomotor effects of amphetamine and morphine induced by food restriction depends on corticosterone secretion. Brain Res 611:352-356 (1993).
75. Badiani A, Morano MI, Akil H, Robinson TE. Circulating adrenal hormones are not necessary for the development of sensitization to the psychomotor activating effects of amphetamine. Brain Res 673:13-24 (1995).
76. 3H]dopamine release. Brain Res 566:255-264 (1991).
77. Robinson TE, Becker JB, Presty SK. Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res 253:231-241 (1982).
78. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247-291 (1993).
79. Yehuda R, Antelman SM. Criteria for rationally evaluating animal models of posttraumatic stress disorder. Biol Psychiatry 33:479-486 (1993).
80. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999-1010 (1992).
81. Bell IR. Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Toxicology 111:101-117 (1996).
82. Beatty J, Greenberg A, Deibler WP. Operant control of occipital theta rhythm affects performance in a radar monitoring task. Science 183:871-873 (1974).
83. Bell IR, Schwartz GE, Peterson JM, Kline JP. Unpublished data.
84. Mann CA, Lubar JF, Zimmerman AW, Miller CA, Muenchen RA. Quantitative analysis of EEC in boys with attention-deficit/hyperactivity disorder: controlled study with clinical implications. Ped Neurol 8:30-36 (1992).
85. Janzen T, Graap K, Stephanson S, Marshall W, Fitzsimmons G. Differences in baseline EEG measures for ADD and normally achieving preadolescent males. Biofeedback Self-Regul 20:65-82 (1995).
86. Bell IR, Miller CS, Schwartz GE, Peterson JM, Amend D. Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Arch Environ Health 51:9-21 (1996).
87. Russell V, deVilliers A, Sagvolden T, Lamm M, Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit/hyperactivity disorder - the spontaneously hypertensive rat. Brain Res 676:343-351 (1995).
88. Bell IR, Schwartz GE, Bootzin RR, Wyatt JK. Time-dependent sensitization of heart rate and blood pressure over multiple laboratory sessions in elderly individuals with chemical odor intolerance. Arch Environ Health (in press).
89. Casale TB, Bowman S, Kaliner M. Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 73:775-781 (1984).
90. Baldwin CM, Bell IR, Lebowitz MD. The association or respiratory problems in a community sample of self-reported chemical intolerance: implications for women's health and quality of life. Eur J Epidemiol (in press).
91. McCubbin JA. Stress and endogenous opioids: behavioral and circulatory interactions. Biol Psychology 35:91-122 (1993).
92. Bell IR, Bootzin RR, Ritenbaugh C, Wyatt JK, DeGiovanni G, Kulinovich T, Anthony J, Kuo TF, Rider SP, Peterson JM, Schwartz GE, Johnson KA. A polysomnographic study of sleep disturbance in community elderly with self-reported environmental chemical odor intolerance. Biol Psychiatry 40:123-133 (1996).
93. Nicholson AN, Pascoe PA. Dopaminergic transmission and the sleep-wakefulness continuum in man. Neuropharmacology 29-411-417 (1990).
94. Coopersmith R, Weihmuller FB, Kirstein CL, Marshall JF, Leon M. Extracellular dopamine increases in the neonatal olfactory bulb during odor preference training. Brain Res 564:149-153 (1991).
95. Martin JB, Reichlin S. Regulation of prolactin secretion and its disorders. In: Clinical Neuroendocrinology. 2nd ed. Philadelphia:FA Davis, 1987;201-225.
96. Gregerson KA, Chuknyiska R, Golesorkhi N. Stimulation of prolactin release by dopamine withdrawal: role of calcium influx. Am J Physiol 267(5 Pt 1):E789-794 (1994).
97. Lozoff B, Felt BT, Nelson EC, Wolf AW, Meltzer HW, Jimenez E. Serum prolactin levels and behavior in infants. Biol Psychiatry 37:4-12 (1995).
98. Bell IR, Schwartz GE, Baldwin CM. Unpublished data.
99. Cohen S, Kessler RC, Gordon LU, eds. Measuring Stress. A Guide for Health and Social Scientists. New York:Oxrord University Press, 1995.
100. Bell IR, Schwartz GE, Baldwin CM, Hardin EE. Neural sensitization and physiological markers in multiple chemical sensitivity. Regul Toxicol Pharmacol 24:S39-S47 (1996).
101. Antelman SM, Caggiula AR, Knopf S, Kocan DJ, Edwards DJ. Amphetamine or haloperidol 2 weeks earlier antagonized the plasma corticosterone response to amphetamine: evidence for the stressful/foreign nature of drugs. Psychopharmacology 107:331-336 (1992).
102. Antelman SM, Kocan D, Knopf S, Edwards DJ, Caggiula AR. One brief exposure to a psychological stressor induces long-lasting, time-dependent sensitization of both the cataleptic and neurochemical responses to haloperidol. Life Sci 51:261-266 (1992).
103. Staudenmayer H, Selner JC, Buhr MP. Double-blind provocation chamber challenges in 20 patients presenting with "multiple chemical sensitivity." Regul Toxicol Pharmacol 18:44-53 (1993).
104. Newlin DB, Pretorius MB. Prior exposures to the laboratory enhance the effect of alcohol. J Stud Alc 52:470-473 (1991).
105. Groves PM, Thompson RF. Habituation: a dual-process theory. Psychol Rev 77:419-450 (1970).
106. Post RM. Intermittent versus continuous stimulation: effect of the interval on the development of sensitization or tolerance. Life Sci 26:1275-1282 (1980).
107. Piazza PV, Maccari S, Deminiere JM, LeMoal M, Mormede P, Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA 88:2088-2092 (1991).
108. Exner E, Clark D. Behavior in the novel environment predicts responsiveness to d-amphetamine in the rat: a multivariate approach. Behav Pharmacol 4:47-56 (1993).
109. Bell IR, Schwartz GE, Baldwin CM, Hardin EE, Kline JP. Unpublished data.